2023
Dengue Fever Surveillance in Mato Grosso do Sul: Insights from Genomic Analysis and Implications for Public Health Strategies
de Arruda L, Giovanetti M, Fonseca V, Zardin M, de Castro Lichs G, Asato S, Esposito A, Müller M, Xavier J, Fritsch H, Lima M, de Oliveira C, Santos E, de Mello Almeida Maziero L, Frias D, Neves D, da Silva L, Barretos E, Oshiro P, Goday B, dos Santos J, Kashima S, de Albuquerque C, do Carmo Said R, Rosewell A, Demarchi L, Croda J, Alcantara L, Gonçalves C. Dengue Fever Surveillance in Mato Grosso do Sul: Insights from Genomic Analysis and Implications for Public Health Strategies. Viruses 2023, 15: 1790. PMID: 37766197, PMCID: PMC10536684, DOI: 10.3390/v15091790.Peer-Reviewed Original ResearchConceptsInforming public health actionOn-site training programDiverse viral lineagesPublic health actionPublic health strategiesMultiple introduction eventsSecretary of HealthMonitoring viral evolutionHealth strategiesHealth actionsGenome sequenceGenomic analysisDynamics of dengue virusTraining programIntroduction eventsGenomic surveillanceViral transmission patternsViral lineagesPublic healthHealthMato GrossoEpidemiological dataViral evolutionPreventive measuresSurveillance activitiesSpread of Mycobacterium tuberculosis in Southern Brazilian persons deprived of liberty: a molecular epidemiology study
Busatto C, Possuelo L, Bierhals D, de Oliveira C, de Souza M, Fanfa D, Barreto É, Schwarzbold P, Von Groll A, Portugal I, Perdigão J, Croda J, Andrews J, da Silva P, Ramis I. Spread of Mycobacterium tuberculosis in Southern Brazilian persons deprived of liberty: a molecular epidemiology study. European Journal Of Clinical Microbiology & Infectious Diseases 2023, 42: 297-304. PMID: 36701032, DOI: 10.1007/s10096-023-04546-4.Peer-Reviewed Original ResearchConceptsAnti-TB drug resistanceM. tuberculosisTB control programsCross-sectional studyM. tuberculosis strainsMolecular epidemiology studiesTB burdenLAM strainsTuberculosis strainsEpidemiology studiesDrug resistanceMycobacterium tuberculosisCentral laboratoryTranslational researchTuberculosisCommon strainControl programsPDLMolecular characterizationHaarlemImproved strategiesPersons
2021
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
Verma R, Patil S, Zhang N, Moreira F, Vitorio M, Santos A, Wallace E, Gnanashanmugam D, Persing D, Savic R, Croda J, Andrews J. A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment. American Journal Of Respiratory And Critical Care Medicine 2021, 204: 1317-1326. PMID: 34375564, DOI: 10.1164/rccm.202103-0564oc.Peer-Reviewed Original ResearchConceptsPharmacogenomic assaysSparse pharmacokinetic samplingInadequate treatment responseInterindividual pharmacokinetic variabilityAcetylation genotypeIsoniazid clearancePharmacokinetic samplingPulmonary tuberculosisWhole blood samplesIntermediate acetylatorsPharmacokinetic variabilityFast acetylatorsNAT2 polymorphismsAcetylator typeSlow acetylatorsTuberculosis treatmentTreatment responseBlood samplesGeneXpert platformTuberculosis diagnosisVariable drug concentrationsHealthy individualsPersonalized dosingSubstantial incidenceStandardized dosing
2020
Prevalence, incidence and associated factors for HBV infection among male and female prisoners in Central Brazil: A multicenter study
Rezende G, Lago B, Puga M, Bandeira L, Pompilio M, Castro V, Tanaka T, Cesar G, Oliveira S, Yassuda R, Simionatto S, Weis S, Basílio S, Croda J, Motta-Castro A. Prevalence, incidence and associated factors for HBV infection among male and female prisoners in Central Brazil: A multicenter study. International Journal Of Infectious Diseases 2020, 96: 298-307. PMID: 32315810, DOI: 10.1016/j.ijid.2020.04.019.Peer-Reviewed Original ResearchConceptsHBV exposureHepatitis B virus infectionHCV/HBVIncidence of HBVHBV serological markersB virus infectionCross-sectional studyGenotypes/subtypesHBV infectionCohort studySerological markersHBV isolatesMulticenter studyHigh prevalenceLower incidenceVirus infectionHigh riskHBVNew casesBlood collectionFemale prisonersInfectionIncidencePreventive measuresPrevalence
2019
Genetic Diversity and Molecular Epidemiology of Mycobacterium tuberculosis in Roraima State, Brazil.
Tatara M, Perdigão J, Viveiros M, Kritski A, Silva K, Sacchi F, de Lima C, Dos Santos P, Diniz J, Almeida Silva P, Gomes P, Gomes M, Cunha E, Lapa E Silva J, Portugal I, Croda J, Andrade M. Genetic Diversity and Molecular Epidemiology of Mycobacterium tuberculosis in Roraima State, Brazil. American Journal Of Tropical Medicine And Hygiene 2019, 101: 774-779. PMID: 31392954, PMCID: PMC6779181, DOI: 10.4269/ajtmh.19-0324.Peer-Reviewed Original ResearchConceptsPopulation-based prospective studyDrug resistanceMolecular epidemiologyResistance profilesRepetitive units-variable numberMTB/RIFDrug susceptibility testDrug resistance profilesTransmission of MtbPublic health policyPhenotypic resistance profilesIsoniazid monoTB preventionProspective studyNew strain typesTB epidemiologyPrimary resistanceHigh prevalenceMTB isolatesProportion methodHealth policyMycobacterium tuberculosisSusceptibility testsTuberculosisVulnerable populations
2016
Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil
Heinrich M, Zembrzuski V, Ota M, Sacchi F, Teixeira R, Acero P, Cunha G, Souza-Santos R, Croda J, Basta P. Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil. Tuberculosis 2016, 101: 15-24. PMID: 27865386, DOI: 10.1016/j.tube.2016.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntitubercular AgentsArylamine N-AcetyltransferaseBrazilChemical and Drug Induced Liver InjuryChildChild, PreschoolCross-Sectional StudiesCytochrome P-450 CYP2E1FemaleGenetic Predisposition to DiseaseGenotypeGlutathione TransferaseHumansIncidenceInfantLongitudinal StudiesMaleMiddle AgedPolymorphism, Single NucleotideTuberculosis, PulmonaryYoung AdultConceptsIncidence of hepatotoxicityAdverse drug reactionsIndigenous patientsAnti-TB drug-induced hepatotoxicityNon-conditional logistic regressionClinical-epidemiological factorsClinical-epidemiological variablesNon-Indigenous patientsGenetic polymorphismsRisk of hepatotoxicityDrug-induced hepatotoxicityPolymorphisms of CYP2E1Anti-tuberculosis drugsAcetylation profileTB patientsSerum levelsDrug reactionsGSTM1 polymorphismOdds ratioLiver enzymesNon-Indigenous populationsTherapeutic schemesPharmacogenetic analysisBetter outcomesPatients